Citadel Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-66,611
| Closed | -$3.91M | – | 15833 |
|
|
2023
Q4 | $3.91M | Sell |
66,611
-1,064,827
| -94% | -$59.9M | ﹤0.01% | 4160 |
|
|
2023
Q3 | $49.3M | Buy |
1,131,438
+649,620
| +135% | +$23.2M | 0.01% | 1086 |
|
|
2023
Q2 | $17.4M | Buy |
481,818
+391,174
| +432% | +$16.1M | ﹤0.01% | 2028 |
|
|
2023
Q1 | $3.37M | Sell |
90,644
-29,859
| -25% | -$1.34M | ﹤0.01% | 4453 |
|
|
2022
Q4 | $5.46M | Buy |
120,503
+31,617
| +36% | +$2.05M | ﹤0.01% | 3710 |
|
|
2022
Q3 | $6.21M | Buy |
88,886
+12,166
| +16% | +$900K | ﹤0.01% | 3527 |
|
|
2022
Q2 | $5.15M | Buy |
76,720
+57,909
| +308% | +$3.68M | ﹤0.01% | 3737 |
|
|
2022
Q1 | $1.55M | Sell |
18,811
-28,338
| -60% | -$2.9M | ﹤0.01% | 6657 |
|
|
2021
Q4 | $6.92M | Buy |
47,149
+9,259
| +24% | +$1.44M | ﹤0.01% | 3739 |
|
|
2021
Q3 | $6.7M | Sell |
37,890
-419,707
| -92% | -$67.5M | ﹤0.01% | 3754 |
|
|
2021
Q2 | $73.9M | Buy |
457,597
+46,382
| +11% | +$7.45M | 0.02% | 848 |
|
|
2021
Q1 | $70.4M | Buy |
411,215
+237,842
| +137% | +$47.1M | 0.02% | 784 |
|
|
2020
Q4 | $38.1M | Buy |
173,373
+160,778
| +1,277% | +$34.8M | 0.01% | 1184 |
|
|
2020
Q3 | $2.09M | Sell |
12,595
-44,787
| -78% | -$6.13M | ﹤0.01% | 4626 |
|
|
2020
Q2 | $6.55M | Sell |
57,382
-27,615
| -32% | -$2.68M | ﹤0.01% | 2709 |
|
|
2020
Q1 | $6.53M | Sell |
84,997
-44,996
| -35% | -$4.04M | ﹤0.01% | 2376 |
|
|
2019
Q4 | $16.8M | Buy |
129,993
+92,686
| +248% | +$8.94M | 0.01% | 1650 |
|
|
2019
Q3 | $2.91M | Sell |
37,307
-167,933
| -82% | -$15.8M | ﹤0.01% | 3885 |
|
|
2019
Q2 | $21.1M | Buy |
205,240
+182,391
| +798% | +$14.2M | 0.01% | 1370 |
|
|
2019
Q1 | $1.67M | Buy |
22,849
+2,425
| +12% | +$165K | ﹤0.01% | 4753 |
|
|
2018
Q4 | $866K | Sell |
20,424
-20,577
| -50% | -$820K | ﹤0.01% | 5529 |
|
|
2018
Q3 | $1.93M | Buy |
41,001
+27,512
| +204% | +$1.53M | ﹤0.01% | 4473 |
|
|
2018
Q2 | $665K | Sell |
13,489
-35,687
| -73% | -$1.35M | ﹤0.01% | 5905 |
|
|
2018
Q1 | $1.51M | Buy |
49,176
+19,128
| +64% | +$531K | ﹤0.01% | 4166 |
|
|
2017
Q4 | $548K | Buy |
30,048
+7,193
| +31% | +$112K | ﹤0.01% | 5513 |
|
|
2017
Q3 | $268K | Buy |
+22,855
| New | +$132K | ﹤0.01% | 6243 |
|
|
2016
Q4 | – | Sell |
-16,493
| Closed | -$109K | – | 8001 |
|
|
2016
Q3 | $109K | Sell |
16,493
-5,571
| -25% | -$29.6K | ﹤0.01% | 6620 |
|
|
2016
Q2 | $120K | Buy |
22,064
+9,258
| +72% | +$148K | ﹤0.01% | 6118 |
|
|
2016
Q1 | $274K | Sell |
12,806
-18,110
| -59% | -$405K | ﹤0.01% | 5215 |
|
|
2015
Q4 | $977K | Sell |
30,916
-91,210
| -75% | -$3.22M | ﹤0.01% | 3606 |
|
|
2015
Q3 | $4.2M | Buy |
+122,126
| New | +$3.69M | ﹤0.01% | 2117 |
|
Other funds holding MRTX
Citadel Advisors's MRTX Position: Q1 2024 in Review
Citadel Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 66,611 shares — an estimated $3.91M sold.
Citadel Advisors first reported a position in MRTX in Q3 2015 and held it in 31 quarters. The position peaked at $73.9M in Q2 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Citadel Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Citadel Advisors sold 66,611 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.91M.
- Citadel Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 31 quarters.
- Citadel Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $73.9M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.